327 related articles for article (PubMed ID: 22594346)
1. Electroclinical biomarkers of early peripheral neurotoxicity from oxaliplatin.
McHugh JC; Tryfonopoulos D; Fennelly D; Crown J; Connolly S
Eur J Cancer Care (Engl); 2012 Nov; 21(6):782-9. PubMed ID: 22594346
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
[TBL] [Abstract][Full Text] [Related]
3. Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies.
Reddy SM; Vergo MT; Paice JA; Kwon N; Helenowski IB; Benson AB; Mulcahy MF; Nimeiri HS; Harden RN
Clin Colorectal Cancer; 2016 Mar; 15(1):37-46. PubMed ID: 26337211
[TBL] [Abstract][Full Text] [Related]
4. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.
Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC
J Clin Oncol; 2009 Mar; 27(8):1243-9. PubMed ID: 19164207
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin-induced neurotoxicity and the development of neuropathy.
Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
Muscle Nerve; 2005 Jul; 32(1):51-60. PubMed ID: 15880395
[TBL] [Abstract][Full Text] [Related]
6. Nerve excitability assessment in chemotherapy-induced neurotoxicity.
Park SB; Lin CS; Kiernan MC
J Vis Exp; 2012 Apr; (62):. PubMed ID: 22565594
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study.
Kokotis P; Schmelz M; Kostouros E; Karandreas N; Dimopoulos MA
Clin Colorectal Cancer; 2016 Sep; 15(3):e133-40. PubMed ID: 27038553
[TBL] [Abstract][Full Text] [Related]
8. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up.
Pietrangeli A; Leandri M; Terzoli E; Jandolo B; Garufi C
Eur Neurol; 2006; 56(1):13-6. PubMed ID: 16825773
[TBL] [Abstract][Full Text] [Related]
9. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients.
Velasco R; Bruna J; Briani C; Argyriou AA; Cavaletti G; Alberti P; Frigeni B; Cacciavillani M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Kalofonos HP
J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):392-8. PubMed ID: 23813745
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.
Griffith KA; Zhu S; Johantgen M; Kessler MD; Renn C; Beutler AS; Kanwar R; Ambulos N; Cavaletti G; Bruna J; Briani C; Argyriou AA; Kalofonos HP; Yerges-Armstrong LM; Dorsey SG
J Pain Symptom Manage; 2017 Nov; 54(5):701-706.e1. PubMed ID: 28743660
[TBL] [Abstract][Full Text] [Related]
11. Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Exp Neurol; 2011 Jan; 227(1):120-7. PubMed ID: 20965170
[TBL] [Abstract][Full Text] [Related]
12. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.
Lersch C; Schmelz R; Eckel F; Erdmann J; Mayr M; Schulte-Frohlinde E; Quasthoff S; Grosskreutz J; Adelsberger H
Clin Colorectal Cancer; 2002 May; 2(1):54-8. PubMed ID: 12453338
[TBL] [Abstract][Full Text] [Related]
13. Late effects of oxaliplatin-induced peripheral neuropathy (LEON)--cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years.
Padman S; Lee J; Kumar R; Slee M; Hakendorf P; Richards A; Koczwara B; Kichenadasse G; Sukumaran S; Roy A; Vatandoust S; Karapetis CS
Support Care Cancer; 2015 Mar; 23(3):861-9. PubMed ID: 25223350
[TBL] [Abstract][Full Text] [Related]
14. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.
Briani C; Argyriou AA; Izquierdo C; Velasco R; Campagnolo M; Alberti P; Frigeni B; Cacciavillani M; Bergamo F; Cortinovis D; Cazzaniga M; Bruna J; Cavaletti G; Kalofonos HP
J Peripher Nerv Syst; 2014 Dec; 19(4):299-306. PubMed ID: 25582667
[TBL] [Abstract][Full Text] [Related]
15. Impact of oxaliplatin-induced neuropathy: a patient perspective.
Bennett BK; Park SB; Lin CS; Friedlander ML; Kiernan MC; Goldstein D
Support Care Cancer; 2012 Nov; 20(11):2959-67. PubMed ID: 22426503
[TBL] [Abstract][Full Text] [Related]
16. Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy.
Chay WY; Tan SH; Lo YL; Ong SY; Ng HC; Gao F; Koo WH; Choo SP
Asia Pac J Clin Oncol; 2010 Dec; 6(4):270-7. PubMed ID: 21114776
[TBL] [Abstract][Full Text] [Related]
17. Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity.
Basso M; Modoni A; Spada D; Cassano A; Schinzari G; Lo Monaco M; Quaranta D; Tonali PA; Barone C
Cancer Chemother Pharmacol; 2011 May; 67(5):1179-87. PubMed ID: 20872144
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin scale and National Cancer Institute-Common Toxicity Criteria in the assessment of chemotherapy-induced peripheral neuropathy.
Kautio AL; Haanpää M; Kautiainen H; Leminen A; Kalso E; Saarto T
Anticancer Res; 2011 Oct; 31(10):3493-6. PubMed ID: 21965767
[TBL] [Abstract][Full Text] [Related]
19. Creatinine clearance rate and nerve conduction velocity are effective in objectively assessing oxaliplatin-neuropathy in patients with colorectal carcinoma.
Hsu TW; Chen FA; Yao YH; Wang WS
Hepatogastroenterology; 2012; 59(117):1441-5. PubMed ID: 22155857
[TBL] [Abstract][Full Text] [Related]
20. Literature review and practical aspects on the management of oxaliplatin-associated toxicity.
Hoff PM; Saad ED; Costa F; Coutinho AK; Caponero R; Prolla G; Gansl RC
Clin Colorectal Cancer; 2012 Jun; 11(2):93-100. PubMed ID: 22154408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
